Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron invested $119.5 million in Truveta ... than 10 times the scale of other health care databases, such as the UK Biobank, which includes 500,000 participants recruited between 2006 ...

Regeneron pledged $119.5m while Illumina is ... interplay between genetics and health in unprecedented detail.” The UK Biobank, which holds genetic and health information from 500,000 ...

Regeneron will sequence the genomes ... the U.S. National Institutes of Health's All of Us Research Program and the UK Biobank. Those databases represent 850,000 and 500,000 participants ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...